Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03650348 · ClinicalTrials.gov registry record · Phase 1
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
A Phase 1 study of HER2-positive Breast Cancer and HER2-positive Gastric Cancer, sponsored by Pieris Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 8
- Study locations
NCT03650348: Completed Phase 1 study of HER2-positive Breast Cancer and HER2-positive Gastric Cancer, sponsored by Pieris Pharmaceuticals.
NCT03650348 is a Phase 1 study of HER2-positive Breast Cancer and HER2-positive Gastric Cancer that has completed, run by Pieris Pharmaceuticals. The registered enrollment target is 41 participants, below the 235-participant average among 58 other HER2-positive Breast Cancer trials with a reported enrollment target (83% lower). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03650348, a Phase 1 study of HER2-positive Breast Cancer and HER2-positive Gastric Cancer, has completed, sponsored by Pieris Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 8
- Study locations
Study Summary
A Phase 1b, open-label, dose escalation study of PRS-343 in combination with atezolizumab in patients with HER2-positive advanced or metastatic solid tumors.
Conditions Studied
Interventions
- DRUG PRS-343 in Combination with Atezolizumab
Study Locations (8)
California
- USC Norris Comprehensive Cancer Center - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport Beach
- UCLA Health - Santa Monica
Texas
- M.D. Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Louisiana
- Ochsner Cancer Institute - New Orleans
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- The Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-08-21 |
| Est. Completion | 2022-08-11 |
| Phase | Phase 1 |
What the finished NCT03650348 record still lists
NCT03650348 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 235-participant average among 58 other HER2-positive Breast Cancer trials with a reported enrollment target (83% lower).
The record links to 4 conditions, with HER2-positive Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which PRS-343 in Combination with Atezolizumab is the first listed.
NCT03650348 lists 8 locations in 5 states (California, Texas, Louisiana).
Frequently Asked Questions
What is clinical trial NCT03650348 about?
NCT03650348 is a clinical study titled "PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors". A Phase 1b, open-label, dose escalation study of PRS-343 in combination with atezolizumab in patients with HER2-positive advanced or metastatic solid tumors.
What is the current status of trial NCT03650348?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2018-08-21. Estimated completion is 2022-08-11.
What conditions does trial NCT03650348 study?
This clinical trial studies the following conditions: HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-Positive Solid Tumor, HER2-positive Bladder Cancer.
What interventions are being tested in trial NCT03650348?
The interventions under investigation include: PRS-343 in Combination with Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT03650348?
This trial is sponsored by Pieris Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03650348 being conducted?
This trial has 8 study locations across California, Louisiana, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03650348's enrollment target sits among peer trials
41 34th of 58 higher than 25 of 58 other HER2-positive Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HER2-positive Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RECRUITING · Phase 1
-
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
RECRUITING · Phase 1
-
HER-2 B Cell Peptide Vaccine
RECRUITING · Phase 1
-
HER2 Vaccine for Locally Advanced Breast Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI